Biogen Current Ratio 2006-2021 | BIIB

Current and historical current ratio for Biogen (BIIB) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Biogen current ratio for the three months ending June 30, 2021 was 2.15.
Biogen Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $7.18B $3.35B 2.15
2021-03-31 $6.72B $3.17B 2.12
2020-12-31 $6.89B $3.74B 1.84
2020-09-30 $7.84B $3.80B 2.06
2020-06-30 $8.49B $3.45B 2.46
2020-03-31 $8.01B $4.64B 1.73
2019-12-31 $8.38B $4.86B 1.72
2019-09-30 $8.45B $4.43B 1.91
2019-06-30 $7.91B $3.21B 2.46
2019-03-31 $8.94B $3.15B 2.84
2018-12-31 $7.64B $3.30B 2.32
2018-09-30 $8.72B $3.18B 2.75
2018-06-30 $7.43B $3.15B 2.36
2018-03-31 $10.20B $3.15B 3.23
2017-12-31 $7.87B $3.37B 2.34
2017-09-30 $7.57B $3.45B 2.20
2017-06-30 $7.11B $3.38B 2.10
2017-03-31 $6.86B $2.99B 2.29
2016-12-31 $8.73B $3.42B 2.55
2016-09-30 $8.09B $2.50B 3.24
2016-06-30 $7.45B $2.52B 2.96
2016-03-31 $7.20B $2.78B 2.59
2015-12-31 $6.70B $2.58B 2.60
2015-09-30 $9.27B $2.63B 3.52
2015-06-30 $5.62B $2.56B 2.20
2015-03-31 $5.26B $1.95B 2.70
2014-12-31 $4.54B $2.22B 2.05
2014-09-30 $4.37B $1.94B 2.25
2014-06-30 $3.93B $1.92B 2.05
2014-03-31 $3.53B $1.59B 2.21
2013-12-31 $3.19B $1.76B 1.81
2013-09-30 $2.64B $1.52B 1.74
2013-06-30 $2.52B $1.30B 1.94
2013-03-31 $5.33B $1.28B 4.16
2012-12-31 $3.24B $1.66B 1.96
2012-09-30 $3.06B $1.52B 2.01
2012-06-30 $2.87B $1.43B 2.00
2012-03-31 $2.68B $1.34B 2.00
2011-12-31 $2.98B $0.91B 3.26
2011-09-30 $2.84B $0.89B 3.21
2011-06-30 $2.69B $0.95B 2.82
2011-03-31 $2.63B $0.98B 2.69
2010-12-31 $2.54B $1.05B 2.42
2010-09-30 $2.13B $0.82B 2.59
2010-06-30 $2.26B $0.76B 2.98
2010-03-31 $2.41B $0.68B 3.53
2009-12-31 $2.48B $0.72B 3.47
2009-09-30 $2.57B $0.72B 3.57
2009-06-30 $2.74B $0.80B 3.41
2009-03-31 $2.48B $0.81B 3.07
2008-12-31 $2.46B $0.92B 2.66
2008-09-30 $2.64B $0.99B 2.68
2008-06-30 $2.16B $0.89B 2.44
2008-03-31 $2.14B $0.71B 3.03
2007-12-31 $2.37B $2.19B 1.08
2007-09-30 $1.62B $1.99B 0.82
2007-06-30 $2.69B $3.47B 0.78
2007-03-31 $1.94B $0.50B 3.88
2006-12-31 $1.71B $0.58B 2.94
2006-09-30 $1.39B $0.50B 2.80
2006-06-30 $1.45B $0.50B 2.90
2006-03-31 $1.60B $0.52B 3.06
2005-12-31 $1.63B $0.60B 2.73
2005-09-30 $1.54B $0.56B 2.75
2005-06-30 $1.80B $0.54B 3.32
2005-03-31 $1.98B $1.23B 1.62
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $43.118B $13.445B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71